Skip to content

    Divi's Lab.

    DIVISLABNeutral
    Healthcare·3 Aug 2024
    Management Summary

    Divi's opened FY25 with solid 18% constant currency growth driven by balanced performance across generics and custom synthesis. Generics contributed 51% reflecting strong volume momentum despite persistent pricing headwinds. Kakinada Phase 1 construction progressing with commercialization expected by FY25-end. The company maintained its strong cash position of ₹4,229 crores while investing in backward integration and peptide capabilities.

    Highlights

    8

    • Q1 FY25 total income grew 18% YoY with constant currency growth at 18%

    • PBT at ₹604 crores vs ₹492 crores YoY; PAT ₹430 crores vs ₹356 crores

    • Product mix: Generics 51%, Custom Synthesis 49%; material consumption at 40%

    • Nutraceutical business at ₹178 crores for the quarter

    • Kakinada Unit-III: ₹1,018 crores spent; ₹837 crores in CWIP; commercialization towards end of FY25

    • Cash on books at ₹4,229 crores; CWIP at ₹1,062 crores

    • Exports at 86% of sales; US+Europe at 70%

    • Generic pricing pressure continues across board but volume growth maintained

    What Changed3

    vs Q2 FY25

    Tone shiftGood → NeutralGuidance items4 → 1 (-3)Risks discussed3 → 2 (-1)

    Key financials

    Single quarter

    02 metrics
    1. 01PBT₹604 Cr+23%YoY
    2. 02PAT₹430 Cr+21%YoY

    Segment breakdown

    Generics
    51% Revenue Share
    Custom Synthesis
    49% Revenue Share
    Nutraceuticals
    ₹178 Cr Q1 Revenue
    Geographic Mix
    86% Export Share70% US+Europe
    Kakinada
    ₹1,018 Cr Total Spent₹1,062 Cr CWIP
    List

    Guidance & targets

    1
    CategoryTargetPriority
    Kakinada
    Commercialization timeline
    Towards end of FY25, phase-wise
    		High

    Risks & concerns

    5
    RiskSeverity

    Generic pricing deflation persists across multiple products

    Industry-wide pricing pressure on core generic portfolio. Volume gains partially offset value decline. — Management acknowledged

    medium

    Product mix shift to generics (51%) from CS may pressure margins

    Material consumption at 40% vs 39% in prior quarter due to mix change. Management views this as quarter-to-quarter variability. — Analyst acknowledged

    low

    Areas of Evasion(3)

    • Specific product revenues
    • CS project details
    • Kakinada benefits timeline

    Q&A highlights

    3

    “Generic pricing pressure persists across broad product portfolio but volumes maintained through market share gains in emerging products”

    Confirms structural pricing challenge but volume resilience provides floor for generic revenue

    asked by Amay (JM Financials)

    1 min read2 chapters

    Detailed Narrative

    01

    Balanced Growth Across Segments

    Q1 FY25 delivered 18% constant currency growth with generics at 51% and CS at 49% of revenue. Generic business maintained volumes through market share gains in emerging products despite persistent pricing pressure across core molecules. Nutraceutical business contributed ₹178 crores. CS pipeline showing increased RFPs from China Plus One and Biosecure Act tailwinds.

    02

    Kakinada and Manufacturing Expansion

    Unit-III Kakinada progressing with ₹1,018 crores spent on 200-acre Phase 1 site. Commercialization expected towards FY25-end with phase-wise start. Facility to support backward integration and free GMP capacity at Unit I and II. Phase 2 consideration on 300 remaining acres dependent on CS pipeline materialization. USFDA inspection readiness maintained across facilities.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.